Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months

NCT00555061 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00555061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00555061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2007
Completion date
August 31, 2008
Enrollment
60 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

skin infections, bacterial